340B Plan B: Pharma Pivots To Rebate Pricing Model After Pharmacy Restrictions Fall Short

 
• By Cathy Kelly
  
Manufacturers are pivoting to back-end rebates in the 340B program. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from Geography